Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Negoro

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2005
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancerY Ohe, S Negoro, K Matsui, et al.
Japanese Journal of Clinical Oncology|October 1, 1996
Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancerS Atagi, K Furuse, M Kawahara, et al.
Circulation|June 1, 1996
Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarctionH Ito, A Okamura, K Iwakura, et al.
The Journal of Biological Chemistry|June 16, 2001
Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathwayM Izumi, Y Fujio, K Kunisada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)K Takeda, S Negoro, T Tamura, et al.
British Journal of Cancer|March 28, 2007
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinibM Satouchi, S Negoro, Y Funada, et al.
British Journal of Cancer|January 1, 1997
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancerM Fukuoka, N Masuda, S Negoro, et al.
British Journal of Cancer|July 17, 1998
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancerK Matsui, N Masuda, M Fukuoka, et al.
The Journal of Biological Chemistry|April 1, 2000
Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytesM Funamoto, Y Fujio, K Kunisada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumorsK Nakagawa, T Tamura, S Negoro, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2005
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancerY Ohe, S Negoro, K Matsui, et al.
Japanese Journal of Clinical Oncology|October 1, 1996
Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancerS Atagi, K Furuse, M Kawahara, et al.
Circulation|June 1, 1996
Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarctionH Ito, A Okamura, K Iwakura, et al.
The Journal of Biological Chemistry|June 16, 2001
Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathwayM Izumi, Y Fujio, K Kunisada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)K Takeda, S Negoro, T Tamura, et al.
British Journal of Cancer|March 28, 2007
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinibM Satouchi, S Negoro, Y Funada, et al.
British Journal of Cancer|January 1, 1997
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancerM Fukuoka, N Masuda, S Negoro, et al.
British Journal of Cancer|July 17, 1998
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancerK Matsui, N Masuda, M Fukuoka, et al.
The Journal of Biological Chemistry|April 1, 2000
Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytesM Funamoto, Y Fujio, K Kunisada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumorsK Nakagawa, T Tamura, S Negoro, et al.
Pageof 20